nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0433	0.415	CbGbCtD
Duloxetine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0346	0.332	CbGbCtD
Duloxetine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0224	0.174	CbGeAlD
Duloxetine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0169	0.162	CbGbCtD
Duloxetine—NPY1R—nerve—peripheral nervous system neoplasm	0.0147	0.114	CbGeAlD
Duloxetine—HTR6—ganglion—peripheral nervous system neoplasm	0.0102	0.079	CbGeAlD
Duloxetine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00951	0.0912	CbGbCtD
Duloxetine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00821	0.0635	CbGeAlD
Duloxetine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.00768	0.0594	CbGeAlD
Duloxetine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00618	0.0478	CbGeAlD
Duloxetine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.0061	0.0472	CbGeAlD
Duloxetine—HTR2C—ganglion—peripheral nervous system neoplasm	0.0059	0.0456	CbGeAlD
Duloxetine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00585	0.0452	CbGeAlD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—PINK1—peripheral nervous system neoplasm	0.00582	0.0644	CbGpPWpGaD
Duloxetine—HTR2A—pons—peripheral nervous system neoplasm	0.00578	0.0447	CbGeAlD
Duloxetine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00559	0.0433	CbGeAlD
Duloxetine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00499	0.0386	CbGeAlD
Duloxetine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00492	0.0381	CbGeAlD
Duloxetine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.00431	0.0476	CbGpPWpGaD
Duloxetine—SLC6A4—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.00389	0.0431	CbGpPWpGaD
Duloxetine—NPY1R—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.00356	0.0394	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.00302	0.0334	CbGpPWpGaD
Duloxetine—HTR2A—nerve—peripheral nervous system neoplasm	0.003	0.0232	CbGeAlD
Duloxetine—HTR2A—ganglion—peripheral nervous system neoplasm	0.00296	0.0229	CbGeAlD
Duloxetine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.00265	0.0205	CbGeAlD
Duloxetine—HTR2C—brainstem—peripheral nervous system neoplasm	0.00256	0.0198	CbGeAlD
Duloxetine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.00243	0.0188	CbGeAlD
Duloxetine—NPY1R—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00224	0.0247	CbGpPWpGaD
Duloxetine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.00214	0.0166	CbGeAlD
Duloxetine—HTR6—Serotonin Receptor 4/6/7 and NR3C Signaling—GNAS—peripheral nervous system neoplasm	0.00204	0.0226	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00187	0.0207	CbGpPWpGaD
Duloxetine—SLC6A4—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00175	0.0194	CbGpPWpGaD
Duloxetine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00152	0.0168	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00151	0.0167	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.0015	0.0166	CbGpPWpGaD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.00141	0.0156	CbGpPWpGaD
Duloxetine—SLC6A3—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	0.00137	0.0152	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00134	0.0148	CbGpPWpGaD
Duloxetine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.00131	0.0101	CbGeAlD
Duloxetine—HTR2A—brainstem—peripheral nervous system neoplasm	0.00129	0.00995	CbGeAlD
Duloxetine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00117	0.00907	CbGeAlD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—TH—peripheral nervous system neoplasm	0.00116	0.0129	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00114	0.0126	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00113	0.0125	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00109	0.0121	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.001	0.0111	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.000879	0.00973	CbGpPWpGaD
Duloxetine—Protriptyline—ABCB1—peripheral nervous system neoplasm	0.000871	0.476	CrCbGaD
Duloxetine—NPY1R—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000847	0.00937	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000741	0.0082	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000674	0.00745	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000645	0.00714	CbGpPWpGaD
Duloxetine—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000634	0.00491	CbGeAlD
Duloxetine—HTR2C—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000615	0.0068	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—peripheral nervous system neoplasm	0.000604	0.00668	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000598	0.00662	CbGpPWpGaD
Duloxetine—Fluoxetine—ABCB1—peripheral nervous system neoplasm	0.000595	0.325	CrCbGaD
Duloxetine—NPY1R—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000586	0.00648	CbGpPWpGaD
Duloxetine—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000578	0.00447	CbGeAlD
Duloxetine—NPY1R—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000562	0.00621	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000553	0.00612	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00055	0.00608	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000539	0.00596	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000534	0.00591	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000528	0.00584	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—peripheral nervous system neoplasm	0.000524	0.0058	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000513	0.00568	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000494	0.00546	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000489	0.00541	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000478	0.00528	CbGpPWpGaD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	0.000474	0.00524	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.000456	0.00504	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000454	0.00502	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000449	0.00496	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000444	0.00491	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.000442	0.00489	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000421	0.00466	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00041	0.00453	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000407	0.00451	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000405	0.00448	CbGpPWpGaD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000404	0.00447	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000404	0.00447	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000403	0.00446	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000402	0.00445	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000402	0.00445	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.000384	0.00424	CbGpPWpGaD
Duloxetine—Propranolol—ABCB1—peripheral nervous system neoplasm	0.000363	0.198	CrCbGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000359	0.00397	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000354	0.00391	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000348	0.00385	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000346	0.00383	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000332	0.00367	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000328	0.00363	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000324	0.00359	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00031	0.00343	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000308	0.00341	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000297	0.00329	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000297	0.00329	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00029	0.00321	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000286	0.00317	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000276	0.00306	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000275	0.00304	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000269	0.00298	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000263	0.00291	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000262	0.0029	CbGpPWpGaD
Duloxetine—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000384	CcSEcCtD
Duloxetine—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000383	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000258	0.00286	CbGpPWpGaD
Duloxetine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000258	0.000382	CcSEcCtD
Duloxetine—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000257	0.000381	CcSEcCtD
Duloxetine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000257	0.000381	CcSEcCtD
Duloxetine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000256	0.00038	CcSEcCtD
Duloxetine—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000377	CcSEcCtD
Duloxetine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000377	CcSEcCtD
Duloxetine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000254	0.000376	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000254	0.00281	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000254	0.0028	CbGpPWpGaD
Duloxetine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.000376	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000373	CcSEcCtD
Duloxetine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000252	0.000373	CcSEcCtD
Duloxetine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000251	0.00278	CbGpPWpGaD
Duloxetine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000251	0.000373	CcSEcCtD
Duloxetine—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.00025	0.00037	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000249	0.00037	CcSEcCtD
Duloxetine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000249	0.00037	CcSEcCtD
Duloxetine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000249	0.000369	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000249	0.00275	CbGpPWpGaD
Duloxetine—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000367	CcSEcCtD
Duloxetine—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000367	CcSEcCtD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000247	0.00273	CbGpPWpGaD
Duloxetine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000247	0.000366	CcSEcCtD
Duloxetine—Pain—Etoposide—peripheral nervous system neoplasm	0.000247	0.000366	CcSEcCtD
Duloxetine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000366	CcSEcCtD
Duloxetine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000366	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000365	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000363	CcSEcCtD
Duloxetine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000245	0.000363	CcSEcCtD
Duloxetine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000244	0.000362	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000244	0.00269	CbGpPWpGaD
Duloxetine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000361	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000242	0.00268	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000242	0.00268	CbGpPWpGaD
Duloxetine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000357	CcSEcCtD
Duloxetine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000356	CcSEcCtD
Duloxetine—HTR2A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.00024	0.00265	CbGpPWpGaD
Duloxetine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000356	CcSEcCtD
Duloxetine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000355	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.000354	CcSEcCtD
Duloxetine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000238	0.000353	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000238	0.00263	CbGpPWpGaD
Duloxetine—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.000353	CcSEcCtD
Duloxetine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000237	0.000352	CcSEcCtD
Duloxetine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000236	0.00035	CcSEcCtD
Duloxetine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000236	0.00035	CcSEcCtD
Duloxetine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000235	0.000349	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000349	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000349	CcSEcCtD
Duloxetine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000233	0.000346	CcSEcCtD
Duloxetine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000233	0.000346	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000346	CcSEcCtD
Duloxetine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000232	0.000345	CcSEcCtD
Duloxetine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.000344	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000343	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.00023	0.00255	CbGpPWpGaD
Duloxetine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00023	0.00034	CcSEcCtD
Duloxetine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000229	0.00034	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00034	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00034	CcSEcCtD
Duloxetine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000228	0.000339	CcSEcCtD
Duloxetine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000228	0.000339	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.000339	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.000339	CcSEcCtD
Duloxetine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000338	CcSEcCtD
Duloxetine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000338	CcSEcCtD
Duloxetine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000336	CcSEcCtD
Duloxetine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000227	0.000336	CcSEcCtD
Duloxetine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000226	0.000336	CcSEcCtD
Duloxetine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000336	CcSEcCtD
Duloxetine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000334	CcSEcCtD
Duloxetine—Rash—Vincristine—peripheral nervous system neoplasm	0.000225	0.000334	CcSEcCtD
Duloxetine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000225	0.000333	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000333	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000332	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000331	CcSEcCtD
Duloxetine—Headache—Vincristine—peripheral nervous system neoplasm	0.000223	0.000331	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.00033	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000329	CcSEcCtD
Duloxetine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.000326	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000326	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000216	0.00239	CbGpPWpGaD
Duloxetine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000216	0.00032	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000216	0.00032	CcSEcCtD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000215	0.00237	CbGpPWpGaD
Duloxetine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000316	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000213	0.000316	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000315	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000314	CcSEcCtD
Duloxetine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000212	0.000314	CcSEcCtD
Duloxetine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000314	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000314	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000313	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000313	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000311	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000311	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000309	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000308	CcSEcCtD
Duloxetine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000207	0.000307	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000307	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000207	0.00229	CbGpPWpGaD
Duloxetine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000307	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000307	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000305	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000305	CcSEcCtD
Duloxetine—Chills—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000303	CcSEcCtD
Duloxetine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000204	0.000303	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000204	0.000302	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000301	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000299	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000201	0.00222	CbGpPWpGaD
Duloxetine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000201	0.000297	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000296	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000296	CcSEcCtD
Duloxetine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000199	0.000295	CcSEcCtD
Duloxetine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000199	0.000295	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000294	CcSEcCtD
Duloxetine—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000294	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000198	0.000293	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000292	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000292	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00029	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00029	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000196	0.00029	CcSEcCtD
Duloxetine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000289	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000288	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000286	CcSEcCtD
Duloxetine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000285	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000284	CcSEcCtD
Duloxetine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000191	0.000283	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000283	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000283	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000282	CcSEcCtD
Duloxetine—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.000281	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000189	0.00209	CbGpPWpGaD
Duloxetine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.000279	CcSEcCtD
Duloxetine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000187	0.000278	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000277	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000276	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000274	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000273	CcSEcCtD
Duloxetine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000184	0.000272	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000272	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000272	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000272	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000183	0.00202	CbGpPWpGaD
Duloxetine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000182	0.00027	CcSEcCtD
Duloxetine—Rash—Etoposide—peripheral nervous system neoplasm	0.000182	0.00027	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000182	0.00027	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000182	0.00201	CbGpPWpGaD
Duloxetine—Headache—Etoposide—peripheral nervous system neoplasm	0.000181	0.000268	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000268	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00018	0.002	CbGpPWpGaD
Duloxetine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000267	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000267	CcSEcCtD
Duloxetine—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000265	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000265	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000264	CcSEcCtD
Duloxetine—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000264	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000263	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000263	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000262	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00026	CcSEcCtD
Duloxetine—HTR2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000175	0.00194	CbGpPWpGaD
Duloxetine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000259	CcSEcCtD
Duloxetine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000257	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000257	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000255	CcSEcCtD
Duloxetine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000172	0.000255	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000254	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000253	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000252	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000251	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000251	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000251	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.00025	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000168	0.00025	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000249	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000248	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000246	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000165	0.00183	CbGpPWpGaD
Duloxetine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000245	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000245	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000244	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000244	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000164	0.00181	CbGpPWpGaD
Duloxetine—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000163	0.000242	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000241	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000162	0.00024	CcSEcCtD
Duloxetine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000162	0.00024	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000239	CcSEcCtD
Duloxetine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000239	CcSEcCtD
Duloxetine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000238	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.00016	0.00177	CbGpPWpGaD
Duloxetine—Shock—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000236	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000159	0.00176	CbGpPWpGaD
Duloxetine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000236	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000159	0.00176	CbGpPWpGaD
Duloxetine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000236	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000235	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000235	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000234	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000233	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000232	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000232	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000232	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000232	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000231	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000156	0.00172	CbGpPWpGaD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.00023	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000229	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000229	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000227	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000153	0.00169	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000152	0.00168	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000152	0.00168	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000151	0.00167	CbGpPWpGaD
Duloxetine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000224	CcSEcCtD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.00015	0.00166	CbGpPWpGaD
Duloxetine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000222	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000222	CcSEcCtD
Duloxetine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000221	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000148	0.00164	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000219	CcSEcCtD
Duloxetine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000219	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000218	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000218	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000217	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000217	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000216	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000145	0.00161	CbGpPWpGaD
Duloxetine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000216	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000215	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000214	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000212	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000211	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000209	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000207	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000207	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000139	0.00154	CbGpPWpGaD
Duloxetine—Pain—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000205	CcSEcCtD
Duloxetine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000205	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000138	0.00153	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000203	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000136	0.0015	CbGpPWpGaD
Duloxetine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000201	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000135	0.0015	CbGpPWpGaD
Duloxetine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.0002	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000198	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000198	CcSEcCtD
Duloxetine—HTR2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000133	0.00147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000133	0.00147	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000196	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000196	CcSEcCtD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.00013	0.00144	CbGpPWpGaD
Duloxetine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000193	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000192	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000192	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000129	0.00143	CbGpPWpGaD
Duloxetine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000191	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.00019	CcSEcCtD
Duloxetine—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.00019	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000128	0.00019	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000128	0.00019	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000128	0.00141	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000126	0.00139	CbGpPWpGaD
Duloxetine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000183	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000182	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000122	0.00135	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000122	0.00135	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000121	0.00134	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000121	0.00134	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000121	0.00133	CbGpPWpGaD
Duloxetine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000177	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000177	CcSEcCtD
Duloxetine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000119	0.00131	CbGpPWpGaD
Duloxetine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000176	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000176	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000117	0.00129	CbGpPWpGaD
Duloxetine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000172	CcSEcCtD
Duloxetine—HTR2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000115	0.00128	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000115	0.00127	CbGpPWpGaD
Duloxetine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000115	0.00017	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000111	0.00123	CbGpPWpGaD
Duloxetine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000164	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000164	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000159	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000159	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000107	0.00118	CbGpPWpGaD
Duloxetine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000157	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000106	0.00117	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000105	0.00116	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000105	0.00116	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000104	0.00115	CbGpPWpGaD
Duloxetine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000153	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000152	CcSEcCtD
Duloxetine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000151	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000151	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000102	0.00113	CbGpPWpGaD
Duloxetine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000101	0.00015	CcSEcCtD
Duloxetine—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.0001	0.00111	CbGpPWpGaD
Duloxetine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	9.91e-05	0.000147	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	9.89e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.71e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.68e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.67e-05	0.00107	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.62e-05	0.00106	CbGpPWpGaD
Duloxetine—Nausea—Epirubicin—peripheral nervous system neoplasm	9.62e-05	0.000143	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.53e-05	0.000141	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.45e-05	0.00105	CbGpPWpGaD
Duloxetine—Rash—Doxorubicin—peripheral nervous system neoplasm	9.45e-05	0.00014	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	9.44e-05	0.00014	CcSEcCtD
Duloxetine—HTR2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.4e-05	0.00104	CbGpPWpGaD
Duloxetine—Headache—Doxorubicin—peripheral nervous system neoplasm	9.39e-05	0.000139	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.35e-05	0.00103	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	9.03e-05	0.000999	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.01e-05	0.000997	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.93e-05	0.000988	CbGpPWpGaD
Duloxetine—Nausea—Doxorubicin—peripheral nervous system neoplasm	8.9e-05	0.000132	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.49e-05	0.000939	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	8.17e-05	0.000903	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.01e-05	0.000886	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	7.88e-05	0.000871	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	7.84e-05	0.000868	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.83e-05	0.000866	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	7.69e-05	0.000851	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.47e-05	0.000826	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.15e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.13e-05	0.000788	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.04e-05	0.000779	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	6.89e-05	0.000762	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.84e-05	0.000757	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.84e-05	0.000757	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.78e-05	0.00075	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.78e-05	0.00075	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.71e-05	0.000742	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	6.61e-05	0.000731	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.58e-05	0.000727	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.25e-05	0.000692	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.21e-05	0.000687	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.21e-05	0.000687	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.19e-05	0.000685	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.98e-05	0.000662	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.9e-05	0.000653	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	5.89e-05	0.000652	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	5.79e-05	0.00064	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.74e-05	0.000635	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.74e-05	0.000635	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.71e-05	0.000632	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.68e-05	0.000629	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.64e-05	0.000624	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	5.55e-05	0.000614	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.47e-05	0.000605	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.43e-05	0.000601	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	5.34e-05	0.000591	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.29e-05	0.000586	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.02e-05	0.000555	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.94e-05	0.000546	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	4.9e-05	0.000543	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	4.7e-05	0.00052	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	4.53e-05	0.000501	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.35e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.35e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.29e-05	0.000474	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.22e-05	0.000467	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.16e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.03e-05	0.000445	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.77e-05	0.000418	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.69e-05	0.000409	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.67e-05	0.000406	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.67e-05	0.000406	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.55e-05	0.000393	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	3.51e-05	0.000388	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.5e-05	0.000387	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.49e-05	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.21e-05	0.000355	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.97e-05	0.000329	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	2.96e-05	0.000328	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.83e-05	0.000313	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.79e-05	0.000308	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.76e-05	0.000305	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.61e-05	0.000289	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.6e-05	0.000287	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.57e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.52e-05	0.000279	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	2.51e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.5e-05	0.000277	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.39e-05	0.000265	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	2.36e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.29e-05	0.000254	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	2.27e-05	0.000252	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.27e-05	0.000251	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	2.23e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.23e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.1e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.03e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.95e-05	0.000216	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.93e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.91e-05	0.000211	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.89e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000206	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.84e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.76e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.69e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.66e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.61e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.6e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.6e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.54e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.53e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.47e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.44e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.35e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.34e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.18e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.13e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.03e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.97e-06	0.00011	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.81e-06	0.000108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.66e-06	9.58e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	6.14e-06	6.79e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	5.2e-06	5.75e-05	CbGpPWpGaD
